TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer

Zhouhong Ge, Maikel P. Peppelenbosch, Dave Sprengers*, Jaap Kwekkeboom

*Corresponding author for this work

Research output: Contribution to journalReview articlePopular

111 Citations (Scopus)
288 Downloads (Pure)


T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer immunotherapy is currently widely being investigated in both pre-clinical and clinical studies. In multiple cancers TIGIT is expressed on tumor-infiltrating cytotoxic T cells, helper T cells, regulatory T cells and NK cells, and its main ligand CD155 is expressed on tumor-infiltrating myeloid cells and upregulated on cancer cells, which contributes to local suppression of immune-surveillance. While single TIGIT blockade has limited anti-tumor efficacy, pre-clinical studies indicate that co-blockade of TIGIT and PD-1/PD-L1 pathway leads to tumor rejection, notably even in anti-PD-1 resistant tumor models. Among inhibitory immune checkpoint molecules, a unique property of TIGIT blockade is that it enhances not only anti-tumor effector T-cell responses, but also NK-cell responses, and reduces the suppressive capacity of regulatory T cells. Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. The first interim results show promise for combined TIGIT and PD-L1 co-blockade in solid cancer patients. In this review, we summarize the current knowledge and identify the gaps in our current understanding of TIGIT’s roles in cancer immunity, and provide, based on these insights, recommendations for its positioning in cancer immunotherapy.

Original languageEnglish
Article number699895
JournalFrontiers in Immunology
Publication statusPublished - 22 Jul 2021

Bibliographical note

Funding Information:
All figures in this review were created with BioRender.com.

Publisher Copyright:
© Copyright © 2021 Ge, Peppelenbosch, Sprengers and Kwekkeboom.


Dive into the research topics of 'TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer'. Together they form a unique fingerprint.

Cite this